Celldex TherapeuticsCLDX +3.43%57 Quick Ratio is 8.92 as of Mar. 2026, which is 23% below its 10-year median of 11.51. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $6.88 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,416 Biotechnology companies, Celldex Therapeutics ranks better than 75.21% on this metric.
Celldex Therapeutics has a quick ratio of 8.92. It generally indicates good short-term financial strength.
The historical rank and industry rank for Celldex Therapeutics's Quick Ratio or its related term are showing as below:
CLDX'
s Quick Ratio Range Over the Past 10 Years
Min: 5.12 Med: 11.51 Max: 31.77
Current: 8.92
During the past 13 years, Celldex Therapeutics's highest Quick Ratio was 31.77. The lowest was 5.12. And the median was 11.51.
CLDX's Quick Ratio is ranked better than 75.21% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs CLDX: 8.92
Celldex Therapeutics (NAS:CLDX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Celldex Therapeutics Quick Ratio Related Terms
Celldex Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Celldex Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Celldex Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celldex Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Celldex Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celldex Therapeutics (CLDX) has a Quick Ratio of 8.92 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Celldex Therapeutics and its competitors. This is 23% below median its historical median of 11.51. Over the past decade, Celldex Therapeutics' Quick Ratio has ranged from 5.12 to 31.77. According to the industry distribution chart, Celldex Therapeutics ranks #351 out of 1416 companies in the Biotechnology industry, placing it in the top 24.8%.
Is Celldex Therapeutics' Quick Ratio too high?
Celldex Therapeutics' current Quick Ratio of 8.92 is 23% below median its 10-year median of 11.51. Over the past 10 years, this metric has ranged from a low of 5.12 to a high of 31.77. The Biotechnology industry median Quick Ratio is 3.60. Celldex Therapeutics' value of 8.92 is 147.8% above this industry median. Based on the distribution chart, Celldex Therapeutics ranks #351 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Quick Ratio compare to IMNM and ELVN?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #351 out of 1416 companies for Quick Ratio. This places Celldex Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Celldex Therapeutics' value of 8.92 is 147.8% above this benchmark. Historically, Celldex Therapeutics' own Quick Ratio has ranged from 5.12 to 31.77 over the past decade. While the company's 10-year median is 11.51 vs. the industry median of 3.60, Celldex Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celldex Therapeutics's current Quick Ratio of 8.92 is 147.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Celldex Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celldex Therapeutics's current Quick Ratio is 8.92, which is 23% below median its own 10-year median of 11.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.88, compared to a current price of $35.23 — trading 412.1% above its estimated fair value. The current Quick Ratio is 8.92, which is 23% below median its 10-year median of 11.51 and 147.8% above the Biotechnology industry median of 3.60. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Quick Ratio is 8.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celldex Therapeutics (CLDX) Overvalued in 2026?
Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued.
The current stock price of $35.23 is trading 412.1% above its estimated GF Value™ of $6.88.
GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.
Key valuation signals for CLDX:
Quick Ratio: 8.92 (23% below median its 10-year median of 11.51)
GF Value™: $6.88 vs. price of $35.23 (412.1% above fair value)
Industry Position: 147.8% above the Biotechnology median (#351 of 1416)
No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score
Get the complete analysis for CLDX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDX has been successfully added to your 
